Development of an Effective Scalable Synthesis of Lumicitabine
Since 2017 he is Scientific Director at Janssen in Process Development department, PDMS China, Shanghai (2-year assignment).
As Chemistry Lead in the process department, he is developing chemical processes for new API (Active Pharmaceutical Ingredient). The ultimate goal consists of transferring these processes to chemical production plant. In relation with Canagliflozin, a new drug approved in US for the treatment of type 2 diabetes, he has developed an innovative catalyst-free C-glycosylation. Current investigations to extend the scope and limitation of this reaction are ongoing.